Marketplace Donate Now Become a Member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 15, 2015 9:30 AM - Nov 17, 2015 5:45 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

12th Annual Meeting DIA Japan 2015

The registrants will have access to presentation PDFs through Tuesday, May 17, 2016.

Back to Agendas

[V6-S4] HTA in Japan – What Should Pharmaceutical Companies Do?

Session Chair(s)

Kenji Adachi, PhD

Medical Affairs - Health Economics and Outcomes Research, Gilead Sciences, Inc., Japan

The discussion of Health Technology Assessment (HTA) implementation in 2016 started in Japan several years ago. In terms of cost effectiveness, the discussion of HTA tends to be focused on drug price suppression, and the discussion is far from original intention of “HTA is the assessment of the value that health technology brings to patients, families, medical field and entire society, and it can be an index for the limited resource/finance allocation.” Further, cost effectiveness is one of the major elements of HTA, and it is expected to become another indicator for patients or physicians to select a treatment. In this session, in anticipation of HTA introduction, current global and Japan situation around HTA is shared, and discuss what pharmaceutical companies should do in clinical development or post marketing stage from a scientific view including patients involvement and other factors.

Speaker(s)

Christine Fletcher, MSc

Christine Fletcher, MSc

VP/Head, Speciality and Primary Care Statistics, GlaxoSmithKline, United Kingdom

Clinical Trial Design, Analysis and Reporting Strategies to Maximize Reimbursement Success <Remote Presentation via Internet>

Nancy Dreyer, MPH, FISPE

Nancy Dreyer, MPH, FISPE

Founder, Dreyer Strategies LLC, United States

Patient-Centric Postmarketing Studies on Safety, Effectiveness and Value

Kotoba Okuyama

Sr. Biometrician, Biostatistics and Research Decision Sciences, MSD K.K., Japan

What Should We Do During Drug Development and Postmarketing When Introducing HTA in Japan?

Toshihiko Aranishi, PhD

Toshihiko Aranishi, PhD

Research Scientist, Health Outcomes/Health Technology Assessment, Eli Lilly Japan K.K, Japan

TBA

Takeru Shiroiwa, PhD

Senior Researcher, Department of Health and Welfare Services, National Institute of Public Health, Japan

Current HTA Discussion for Japan’s Health Care Policy, and Roles of Academia

Have an account?